Published in Cancer Discov on October 08, 2015
RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-κB pathway, independently of the fusion oncoprotein. Oncotarget (2016) 0.76
RNF2 E3 or Not to E3: Dual Roles of RNF2 Overexpression in Melanoma. Cancer Discov (2015) 0.75
LTBP2 is a prognostic marker in head and neck squamous cell carcinoma. Oncotarget (2016) 0.75
Knockdown of RNF2 induces cell cycle arrest and apoptosis in prostate cancer cells through the upregulation of TXNIP. Oncotarget (2016) 0.75
MYSM1/2A-DUB is an epigenetic regulator in human melanoma and contributes to tumor cell growth. Oncotarget (2017) 0.75
A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
Role of histone H2A ubiquitination in Polycomb silencing. Nature (2004) 9.48
ChromHMM: automating chromatin-state discovery and characterization. Nat Methods (2012) 7.66
Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer (2010) 6.27
Polycomb group proteins Ring1A/B link ubiquitylation of histone H2A to heritable gene silencing and X inactivation. Dev Cell (2004) 5.72
The RCAF complex mediates chromatin assembly during DNA replication and repair. Nature (1999) 5.27
Ring1B compacts chromatin structure and represses gene expression independent of histone ubiquitination. Mol Cell (2010) 4.69
Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res (2005) 3.30
A high-throughput chromatin immunoprecipitation approach reveals principles of dynamic gene regulation in mammals. Mol Cell (2012) 3.04
Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat Struct Mol Biol (2011) 3.00
The dynamic roles of TGF-β in cancer. J Pathol (2010) 2.32
The polycomb protein Ring1B generates self atypical mixed ubiquitin chains required for its in vitro histone H2A ligase activity. Mol Cell (2006) 2.26
Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab Sci (2004) 2.11
Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell (2011) 1.99
The INO80 chromatin remodeling complex in transcription, replication and repair. Trends Biochem Sci (2008) 1.96
Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer (2007) 1.54
LTBPs, more than just an escort service. J Cell Biochem (2012) 1.37
Role of polycomb proteins Ring1A and Ring1B in the epigenetic regulation of gene expression. Int J Dev Biol (2009) 1.29
Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays. Mod Pathol (2006) 1.27
The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma. J Pathol (2009) 1.22
PRC1 and PRC2 are not required for targeting of H2A.Z to developmental genes in embryonic stem cells. PLoS One (2012) 1.14
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest (2015) 1.11
Latent transforming growth factor-beta-binding protein 2 is an adhesion protein for melanoma cells. J Biol Chem (2003) 1.10
Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Mol Cancer Res (2011) 1.04
H1 and HMGB1: modulators of chromatin structure. Biochem Soc Trans (2012) 1.02
Cutaneous melanoma: a model to study cancer metastasis. J Surg Oncol (2011) 0.94
RNF2 is the target for phosphorylation by the p38 MAPK and ERK signaling pathways. Proteomics (2009) 0.88
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov (2015) 1.64
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov (2015) 1.30
Uveal melanoma: From diagnosis to treatment and the science in between. Cancer (2016) 0.95
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Res (2015) 0.86
Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. Mol Cancer Ther (2016) 0.75
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: an Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov (2017) 0.75